N4P — N4 Pharma Share Price
Last trade - 00:00- £2.02m
- £0.84m
- £0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.61 | ||
| Price to Tang. Book | 1.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 344 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.28% | ||
| Return on Equity | -83.28% | ||
| Operating Margin | -21667.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | 0 | n/a | n/a | -51.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 6th, 1979
- Public Since
- June 7th, 2005
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 537,560,699
- Address
- Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ
- Web
- https://www.n4pharma.com/
- Phone
- +44 1332690061
- Auditors
- Saffery Champness LLP
Latest News for N4P
Upcoming Events for N4P
N4 Pharma PLC Annual Shareholders Meeting
Full Year 2024 N4 Pharma PLC Earnings Release
N4 Pharma PLC Annual Shareholders Meeting
Half Year 2025 N4 Pharma PLC Earnings Release
Similar to N4P
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 22:10 UTC, shares in N4 Pharma are trading at 0.38p. This share price information is delayed by 15 minutes.
Shares in N4 Pharma last closed at 0.38p and the price had moved by -54.55% over the past 365 days. In terms of relative price strength the N4 Pharma share price has underperformed the FTSE All Share Index by -56.33% over the past year.
There is no consensus recommendation for this security.
Find out moreN4 Pharma does not currently pay a dividend.
N4 Pharma does not currently pay a dividend.
N4 Pharma does not currently pay a dividend.
To buy shares in N4 Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 0.38p, shares in N4 Pharma had a market capitalisation of £2.02m.
Here are the trading details for N4 Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: N4P
Based on an overall assessment of its quality, value and momentum N4 Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like N4 Pharma. Over the past six months, its share price has underperformed the FTSE All Share Index by -36.49%.
As of the last closing price of 0.38p, shares in N4 Pharma were trading -32.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The N4 Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 0.38p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
N4 Pharma's management team is headed by:
- John Chiplin - NEC
- Nigel Theobald - CEO
- Luke Cairns - EDR
- David Templeton - EDR
- Christopher Britten - NED